ACADIA Pharmaceuticals Announces Top-line Results from Phase 3 ENHANCE Trial of Pimavanserin as Adjunctive Treatment for Patients with Schizophrenia - Benzinga

Submitted by Anonymous (not verified) on Mon, 07/22/2019 - 20:05

ACADIA Pharmaceuticals Announces Top-line Results from Phase 3 ENHANCE Trial of Pimavanserin as Adjunctive Treatment for Patients with Schizophrenia  BenzingaPimavanserin did not achieve statistical significance on the primary endpoint, but showed a consistent trend in improvement of psychotic symptoms ...